Heparin pretreatment in ST segment elevation myocardial infarction: a systematic review and meta-analysis
Gonçalo Costa1,2, Bernardo Resende1, Bárbara Oliveiros2,3
1Serviço de Cardiologia, Centro Hospitalar e Universitário de Coimbra.
Coronary Artery Disease
|August 8, 2024
Summary
Pretreating ST segment elevation myocardial infarction (STEMI) patients with unfractionated heparin (UFH) before percutaneous coronary intervention reduces mortality and cardiogenic shock. This strategy also enhances reperfusion and decreases major bleeding events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Unfractionated heparin (UFH) is commonly used before percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients.
- Current guidelines lack clear recommendations for UFH pretreatment prior to catheterization lab arrival.
Conclusions:
- UFH pretreatment in STEMI patients undergoing primary PCI is linked to reduced all-cause mortality and cardiogenic shock.
- The strategy improves reperfusion rates and appears to diminish major bleeding complications.
- Findings support the consideration of UFH pretreatment in STEMI patients awaiting primary PCI.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502